What is DexCom's SG&A?

DexCom (DXCM) reported SG&A of $358.7M in Q2 2026.

How has DexCom's SG&A changed year-over-year?

DexCom's SG&A increased by 9.4% year-over-year, from $328M to $358.7M.

What is the long-term trend for DexCom's SG&A?

Over 4 years (2021 to 2025), DexCom's SG&A has grown at a 12.3% compound annual growth rate (CAGR), from $811M to $1.29B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

DexCom DXCM SG&A

SG&A at other companies

Frequency ElectronicsFEIM

$4.6M+72.1%

SOL

SOLSSOLS

$108M+16.1%

Cabot CorporationCBT

$67M+4.7%

Orion Group HoldingsORN

$24.4M+7.1%

BlueLinx HoldingsBXC

$96.2M+2.2%

NOVA, Inc.NOV

$328M+8.3%

Other financials

Income statement

See full

Revenue$1.3B+13.1%

Gross profit$830.0M+20.5%

Operating income$318.3M+49.7%

Net income$249.1M+38.5%

EPS (diluted)$0.64+42.2%

Balance sheet

See full

Cash & equivalents$1.1B-4.8%

Total debt$103.3M-23.1%

Total equity$2.6B+1.9%

Total assets$6.5B-11.9%

Cash flow

See full

Operating cash flow$525.6M+186%

CapEx$76.6M-12.0%

Free cash flow$449.0M+364%

Valuation

See full

Market cap$28.88B-17.0%

Enterprise value$27.88B-17.4%

P/E28.9×-32.0×

P/S5.8×-2.3×

Profitability

See full

Gross margin62.5%+3.7pp

Operating margin22.9%+6.9pp

Net margin20.1%+6.8pp

FCF margin29.7%+15.8pp

Returns & leverage

See full

Return on equity38.5%+15.7pp

Debt / equity0×0.0×

Current ratio1.7×+0.2×

Where this comes from

Reported directly by DexCom in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: DexCom’s 8-K, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DexCom's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is DexCom's SG&A?: DexCom (DXCM) reported SG&A of $358.7M in Q2 2026.
How has DexCom's SG&A changed year-over-year?: DexCom's SG&A increased by 9.4% year-over-year, from $328M to $358.7M.
What is the long-term trend for DexCom's SG&A?: Over 4 years (2021 to 2025), DexCom's SG&A has grown at a 12.3% compound annual growth rate (CAGR), from $811M to $1.29B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.